View printer-friendly version |
Charles River Laboratories Announces Third-Quarter 2019 Results
– Third-Quarter Revenue of
– Third-Quarter GAAP Earnings per Share of
– Updates 2019 Guidance –
Acquisitions, which principally included Citoxlab, contributed 7.5% to consolidated third-quarter revenue growth. The impact of foreign currency translation reduced reported revenue growth by 1.3%. Excluding the effect of these items, organic revenue growth of 7.9% was driven by contributions from all three business segments.
On a GAAP basis, third-quarter net income from continuing operations attributable to common shareholders was
On a non-GAAP basis, net income from continuing operations was
“We are the early-stage CRO partner of choice for our clients’ drug research, development, and manufacturing support efforts due to our extensive scientific expertise, which we believe is unique and unparalleled in the early-stage CRO universe. The investments that we have made have also created a more efficient and responsive organization that provides flexible, customized solutions to our clients. We believe we are well positioned to maintain and enhance our market leadership position, as well as to achieve our long-term strategic and financial goals and generate greater shareholder returns,” Mr. Foster concluded.
Third-Quarter Segment Results
Research Models and Services (RMS)
Revenue for the RMS segment was
In the third quarter of 2019, the RMS segment’s GAAP operating margin increased to 25.9% from 25.3% in the third quarter of 2018. On a non-GAAP basis, the operating margin increased to 26.5% from 25.9% in the third quarter of 2018. The GAAP and non-GAAP operating margin increases were driven primarily by the research models business and ongoing operating efficiency initiatives, partially offset by the large IS government contract.
Discovery and Safety Assessment (DSA)
Revenue for the DSA segment was
In the third quarter of 2019, the DSA segment’s GAAP operating margin decreased to 15.5% from 17.9% in the third quarter of 2018. The GAAP operating margin decline was driven primarily by acquisition-related costs primarily related to the Citoxlab acquisition, including amortization of intangible assets. On a non-GAAP basis, the operating margin decreased to 22.1% from 22.6% in the third quarter of 2018. The non-GAAP operating margin decline was driven primarily by the acquisition of Citoxlab, which has a lower operating margin than the legacy Safety Assessment business.
Manufacturing Support (Manufacturing)
Revenue for the Manufacturing segment was
In the third quarter of 2019, the Manufacturing segment’s GAAP operating margin increased to 34.0% from 31.3% in the third quarter of 2018. On a non-GAAP basis, the operating margin increased to 36.4% from 33.4% in the third quarter of 2018. The GAAP and non-GAAP operating margin increases were driven primarily by enhanced operating efficiency in the Microbial Solutions business and operating leverage from higher revenue in Biologics Testing Solutions business.
Updates 2019 Guidance
The Company is updating 2019 financial guidance, which was previously provided on
The moderated revenue growth guidance reflects two primary factors: a greater headwind from foreign exchange that reduces the reported growth rate and a slight moderation of the organic revenue growth outlook. The Company continues to expect organic revenue growth will be in the high-single-digit range in 2019, and within the same ranges as its previous guidance for each of the business segments.
The Company is narrowing its GAAP earnings per share guidance to the lower end of its previous range due primarily to higher acquisition-related and efficiency costs, partially offset by the non-cash, discrete tax benefit in the third quarter related to its international financing structure. Non-GAAP earnings per share guidance is being narrowed to the upper end of the previous range to reflect the Company’s third-quarter operating performance.
The Company’s revenue, earnings per share, and free cash flow guidance is as follows:
2019 GUIDANCE |
CURRENT |
PRIOR |
Revenue growth, reported |
15.0% - 15.5% |
16% - 17% |
Less: Contribution from acquisitions (1) |
8.5% - 9.0% |
8.5% - 9.0% |
Add: Negative impact of foreign exchange |
1.5% - 2.0% |
1.0% - 1.5% |
Revenue growth, organic (2) |
8.25% - 8.75% |
8.5% - 9.5% |
GAAP EPS estimate |
$4.65-$4.75 |
$4.65-$4.80 |
Amortization of intangible assets (3) |
~$1.35 |
$1.35-$1.40 |
Charges related to global efficiency initiatives (4) |
$0.20-$0.25 |
~$0.07 |
Acquisition-related adjustments (5) |
$0.72-$0.75 |
$0.40-$0.45 |
Other items (6) |
~$0.05 |
~$0.03 |
Venture capital investment (gains)/losses (7) |
(~$0.08) |
(~$0.09) |
Discrete tax benefit (8) |
($0.41) |
-- |
Non-GAAP EPS estimate |
$6.50 - $6.60 |
$6.45 - $6.60 |
Free cash flow (9) |
$310 - $320 million |
$310 - $320 million |
Footnotes to Guidance Table:
(1) The contribution from acquisitions reflects only those acquisitions which have been completed.
(2) Organic revenue growth is defined as reported revenue growth adjusted for acquisitions and foreign currency translation.
(3) Amortization of intangible assets includes an estimate of approximately
(4) These charges, which primarily include severance and other costs, relate primarily to the Company’s planned efficiency initiatives. Other projects in support of global productivity and efficiency initiatives are expected, but these charges reflect only the decisions that have already been finalized.
(5) These adjustments are related to the evaluation and integration of acquisitions, and primarily include transaction, advisory, and certain third-party integration costs, as well as certain costs associated with acquisition-related efficiency initiatives. In addition, these adjustments include a charge associated with modification of a purchase option for the remaining 8% equity interest in
(6) Other items include third-party costs, net of insurance reimbursements, associated with the remediation of the unauthorized access into the Company’s information systems, which was detected in
(7) Venture capital investment performance only includes recognized gains or losses. The Company does not forecast future venture capital investment gains or losses.
(8) This item includes a non-cash, discrete tax benefit related to the Company’s international financing structure. The Company recorded a
(9) The reconciliation of the current 2019 free cash flow guidance is as follows: Cash flow from operating activities of
Webcast
Charles River has scheduled a live webcast on
Non-GAAP Reconciliations/Discontinued Operations
The Company reports non-GAAP results in this press release, which exclude often-one-time charges and other items that are outside of normal operations. A reconciliation of GAAP to non-GAAP results is provided in the schedules at the end of this press release. In addition, the Company reports results from continuing operations, which exclude results of the Phase I clinical business that was divested in 2011. The Phase I business is reported as a discontinued operation.
Use of Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, such as non-GAAP earnings per diluted share, which exclude the amortization of intangible assets, and other charges related to our acquisitions; expenses associated with evaluating and integrating acquisitions and divestitures, as well as fair value adjustments associated with contingent consideration; charges, gains, and losses attributable to businesses or properties we plan to close, consolidate, or divest; severance and other costs associated with our efficiency initiatives; the write-off of deferred financing costs and fees related to debt financing; third-party costs associated with the remediation of unauthorized access into our information systems detected in
Caution Concerning Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding the projected future financial performance of Charles River and our specific businesses, including revenue (on both a reported, constant-currency, and organic growth basis), operating margins, earnings per share, the expected impact of foreign exchange rates, and the expected benefit of our life science venture capital investments; the future demand for drug discovery and development products and services, including our expectations for future revenue trends; our expectations with respect to the impact of acquisitions, including the acquisition of Citoxlab, on the Company, our service offerings, client perception, strategic relationships, revenue, revenue growth rates, and earnings; the development and performance of our services and products, including our investments in our portfolio; market and industry conditions including the outsourcing of services and spending trends by our clients; the potential outcome of and impact to our business and financial operations due to litigation and legal proceedings; the impact of U.S. tax reform enacted in the fourth quarter of 2017; and Charles River’s future performance as delineated in our forward-looking guidance, and particularly our expectations with respect to revenue, the impact of foreign exchange, and enhanced efficiency initiatives. Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the ability to successfully integrate businesses we acquire; risks and uncertainties associated with the unauthorized access into its information systems reported on
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ||||||||||||||||||||
SCHEDULE 1 CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (in thousands, except for per share data) |
||||||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||||||
September 28, 2019 | September 29, 2018 | September 28, 2019 | September 29, 2018 | |||||||||||||||||
Service revenue |
$ |
|
523,169 |
|
$ |
|
443,038 |
|
$ |
|
1,479,991 |
|
$ |
|
1,226,948 |
|
||||
Product revenue |
|
144,782 |
|
|
142,257 |
|
|
450,097 |
|
|
437,618 |
|
||||||||
Total revenue |
|
667,951 |
|
|
585,295 |
|
|
1,930,088 |
|
|
1,664,566 |
|
||||||||
Costs and expenses: | ||||||||||||||||||||
Cost of services provided (excluding amortization of intangible assets) |
|
351,894 |
|
|
298,018 |
|
|
1,014,063 |
|
|
844,130 |
|
||||||||
Cost of products sold (excluding amortization of intangible assets) |
|
69,941 |
|
|
71,077 |
|
|
220,028 |
|
|
206,786 |
|
||||||||
Selling, general and administrative |
|
129,509 |
|
|
113,033 |
|
|
388,024 |
|
|
336,936 |
|
||||||||
Amortization of intangible assets |
|
23,805 |
|
|
18,805 |
|
|
65,611 |
|
|
47,813 |
|
||||||||
Operating income |
|
92,802 |
|
|
84,362 |
|
|
242,362 |
|
|
228,901 |
|
||||||||
Other income (expense): | ||||||||||||||||||||
Interest income |
|
385 |
|
|
230 |
|
|
838 |
|
|
694 |
|
||||||||
Interest expense |
|
(5,698 |
) |
|
(17,197 |
) |
|
(36,520 |
) |
|
(47,031 |
) |
||||||||
Other (expense) income, net |
|
(14,254 |
) |
|
5,910 |
|
|
(8,161 |
) |
|
24,069 |
|
||||||||
Income from continuing operations, before income taxes |
|
73,235 |
|
|
73,305 |
|
|
198,519 |
|
|
206,633 |
|
||||||||
(Benefit) provision for income taxes |
|
(317 |
) |
|
12,403 |
|
|
24,970 |
|
|
39,613 |
|
||||||||
Income from continuing operations, net of income taxes |
|
73,552 |
|
|
60,902 |
|
|
173,549 |
|
|
167,020 |
|
||||||||
Income from discontinued operations, net of income taxes | — | — | — |
|
1,506 |
|
||||||||||||||
Net income |
|
73,552 |
|
|
60,902 |
|
|
173,549 |
|
|
168,526 |
|
||||||||
Less: Net income attributable to noncontrolling interests |
|
742 |
|
|
534 |
|
|
1,878 |
|
|
1,818 |
|
||||||||
Net income attributable to common shareholders |
$ |
|
72,810 |
|
$ |
|
60,368 |
|
$ |
|
171,671 |
|
$ |
|
166,708 |
|
||||
Earnings per common share | ||||||||||||||||||||
Basic: | ||||||||||||||||||||
Continuing operations attributable to common shareholders |
$ |
|
1.49 |
|
$ |
|
1.25 |
|
$ |
|
3.53 |
|
$ |
|
3.43 |
|
||||
Discontinued operations |
$ |
— |
$ |
— |
$ |
— |
$ |
0.03 |
|
|||||||||||
Net income attributable to common shareholders |
$ |
|
1.49 |
|
$ |
|
1.25 |
|
$ |
|
3.53 |
|
$ |
|
3.47 |
|
||||
Diluted: | ||||||||||||||||||||
Continuing operations attributable to common shareholders |
$ |
|
1.46 |
|
$ |
|
1.22 |
|
$ |
|
3.46 |
|
$ |
|
3.36 |
|
||||
Discontinued operations |
$ |
— |
$ |
— |
$ |
— |
$ |
0.03 |
|
|||||||||||
Net income attributable to common shareholders |
$ |
|
1.46 |
|
$ |
|
1.22 |
|
$ |
|
3.46 |
|
$ |
|
3.39 |
|
||||
Weighted-average number of common shares outstanding; | ||||||||||||||||||||
Basic |
|
48,818 |
|
|
48,310 |
|
|
48,682 |
|
|
48,098 |
|
||||||||
Diluted |
|
49,715 |
|
|
49,326 |
|
|
49,627 |
|
|
49,118 |
|
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ||||||||
SCHEDULE 2 CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in thousands) |
||||||||
September 28, 2019 | December 29, 2018 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents |
$ |
164,759 |
|
$ |
195,442 |
|
||
Trade receivables, net |
|
524,074 |
|
|
472,248 |
|
||
Inventories |
|
155,526 |
|
|
127,892 |
|
||
Prepaid assets |
|
51,274 |
|
|
53,447 |
|
||
Other current assets |
|
76,774 |
|
|
48,807 |
|
||
Total current assets |
|
972,407 |
|
|
897,836 |
|
||
Property, plant and equipment, net |
|
1,008,047 |
|
|
932,877 |
|
||
Operating lease right-of-use assets, net |
|
140,359 |
|
— | ||||
Goodwill |
|
1,521,619 |
|
|
1,247,133 |
|
||
Client relationships, net |
|
620,868 |
|
|
537,945 |
|
||
Other intangible assets, net |
|
81,257 |
|
|
72,943 |
|
||
Deferred tax assets |
|
44,831 |
|
|
23,386 |
|
||
Other assets |
|
193,174 |
|
|
143,759 |
|
||
Total assets |
$ |
4,582,562 |
|
$ |
3,855,879 |
|
||
Liabilities, Redeemable Noncontrolling Interests and Equity | ||||||||
Current liabilities: | ||||||||
Current portion of long-term debt and finance leases |
$ |
33,611 |
|
$ |
31,416 |
|
||
Accounts payable |
|
107,231 |
|
|
66,250 |
|
||
Accrued compensation |
|
130,292 |
|
|
137,212 |
|
||
Deferred revenue |
|
166,095 |
|
|
145,139 |
|
||
Accrued liabilities |
|
130,015 |
|
|
106,925 |
|
||
Other current liabilities |
|
114,402 |
|
|
71,280 |
|
||
Total current liabilities |
|
681,646 |
|
|
558,222 |
|
||
Long-term debt, net and finance leases |
|
1,882,593 |
|
|
1,636,598 |
|
||
Operating lease right-of-use liabilities |
|
116,868 |
|
— | ||||
Deferred tax liabilities |
|
165,480 |
|
|
143,635 |
|
||
Other long-term liabilities |
|
171,243 |
|
|
179,121 |
|
||
Total liabilities |
|
3,017,830 |
|
|
2,517,576 |
|
||
Redeemable noncontrolling interests |
|
28,345 |
|
|
18,525 |
|
||
Equity: | ||||||||
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding | — | — | ||||||
Common stock, $0.01 par value; 120,000 shares authorized; 48,976 shares issued and 48,837 shares outstanding as of September 28, 2019, and 48,210 shares issued and 48,209 shares outstanding as of December 29, 2018 |
|
490 |
|
|
482 |
|
||
Additional paid-in capital |
|
1,514,620 |
|
|
1,447,512 |
|
||
Retained earnings |
|
213,767 |
|
|
42,096 |
|
||
Treasury stock, at cost, 139 and 1 shares, as of September 28, 2019 and December 29, 2018, respectively |
|
(18,094 |
) |
|
(55 |
) |
||
Accumulated other comprehensive loss |
|
(178,470 |
) |
|
(172,703 |
) |
||
Total equity attributable to common shareholders |
|
1,532,313 |
|
|
1,317,332 |
|
||
Noncontrolling interest |
|
4,074 |
|
|
2,446 |
|
||
Total equity |
|
1,536,387 |
|
|
1,319,778 |
|
||
Total liabilities, redeemable noncontrolling interests and equity |
$ |
4,582,562 |
|
$ |
3,855,879 |
|
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ||||||||
SCHEDULE 3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands) |
||||||||
Nine Months Ended | ||||||||
September 28, 2019 | September 29, 2018 | |||||||
Cash flows relating to operating activities | ||||||||
Net income |
$ |
173,549 |
|
$ |
168,526 |
|
||
Less: Income from discontinued operations, net of income taxes | — |
|
1,506 |
|
||||
Income from continuing operations, net of income taxes |
|
173,549 |
|
|
167,020 |
|
||
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities: | ||||||||
Depreciation and amortization |
|
146,262 |
|
|
120,198 |
|
||
Stock-based compensation |
|
43,429 |
|
|
35,908 |
|
||
Deferred income taxes |
|
(25,092 |
) |
|
(10,385 |
) |
||
Gain on venture capital investments |
|
(5,724 |
) |
|
(22,760 |
) |
||
Other, net |
|
4,865 |
|
|
10,036 |
|
||
Changes in assets and liabilities: | ||||||||
Trade receivables, net |
|
(24,491 |
) |
|
(30,318 |
) |
||
Inventories |
|
(12,981 |
) |
|
(10,340 |
) |
||
Accounts payable |
|
24,481 |
|
|
(5,322 |
) |
||
Accrued compensation |
|
(23,320 |
) |
|
6,088 |
|
||
Deferred revenue |
|
(1,556 |
) |
|
33,491 |
|
||
Customer contract deposits |
|
(7,586 |
) |
|
34,455 |
|
||
Other assets and liabilities, net |
|
8,423 |
|
|
(26,904 |
) |
||
Net cash provided by operating activities |
|
300,259 |
|
|
301,167 |
|
||
Cash flows relating to investing activities | ||||||||
Acquisition of businesses and assets, net of cash acquired |
|
(515,647 |
) |
|
(822,611 |
) |
||
Capital expenditures |
|
(76,675 |
) |
|
(71,378 |
) |
||
Purchases of investments and contributions to venture capital investments |
|
(17,664 |
) |
|
(20,535 |
) |
||
Proceeds from sale of investments |
|
15 |
|
|
30,595 |
|
||
Other, net |
|
(660 |
) |
|
(118 |
) |
||
Net cash used in investing activities |
|
(610,631 |
) |
|
(884,047 |
) |
||
Cash flows relating to financing activities | ||||||||
Proceeds from long-term debt and revolving credit facility |
|
2,071,175 |
|
|
2,392,201 |
|
||
Proceeds from exercises of stock options |
|
26,982 |
|
|
30,228 |
|
||
Payments on long-term debt, revolving credit facility, and finance lease obligations |
|
(1,798,620 |
) |
|
(1,832,805 |
) |
||
Payment of debt financing costs | — |
|
(18,337 |
) |
||||
Purchase of treasury stock |
|
(18,040 |
) |
|
(13,791 |
) |
||
Other, net |
|
(10,516 |
) |
— | ||||
Net cash provided by financing activities |
|
270,981 |
|
|
557,496 |
|
||
Discontinued operations | ||||||||
Net cash used in operating activities from discontinued operations | — |
|
(3,735 |
) |
||||
Effect of exchange rate changes on cash, cash equivalents, and restricted cash |
|
8,793 |
|
|
4,664 |
|
||
Net change in cash, cash equivalents, and restricted cash |
|
(30,598 |
) |
|
(24,455 |
) |
||
Cash, cash equivalents, and restricted cash, beginning of period |
|
197,318 |
|
|
166,331 |
|
||
Cash, cash equivalents, and restricted cash, end of period |
$ |
166,720 |
|
$ |
141,876 |
|
||
Supplemental cash flow information: | ||||||||
Cash and cash equivalents |
$ |
164,759 |
|
$ |
138,866 |
|
||
Restricted cash included in Other current assets |
|
534 |
|
|
426 |
|
||
Restricted cash included in Other assets |
|
1,427 |
|
|
2,584 |
|
||
Cash, cash equivalents, and restricted cash, end of period |
$ |
166,720 |
|
$ |
141,876 |
|
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ||||||||||||||||
SCHEDULE 4 RECONCILIATION OF GAAP TO NON-GAAP SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)(1) (in thousands, except percentages) |
||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 28, 2019 | September 29, 2018 | September 28, 2019 | September 29, 2018 | |||||||||||||
Research Models and Services | ||||||||||||||||
Revenue |
$ |
132,546 |
|
$ |
126,811 |
|
$ |
405,772 |
|
$ |
391,195 |
|
||||
Operating income |
|
34,385 |
|
|
32,121 |
|
|
103,729 |
|
|
104,893 |
|
||||
Operating income as a % of revenue |
|
25.9 |
% |
|
25.3 |
% |
|
25.6 |
% |
|
26.8 |
% |
||||
Add back: | ||||||||||||||||
Amortization related to acquisitions |
|
341 |
|
|
385 |
|
|
1,042 |
|
|
1,202 |
|
||||
Severance |
|
381 |
|
|
65 |
|
|
1,106 |
|
|
808 |
|
||||
Acquisition related adjustments (2) | — | — |
|
2,201 |
|
— | ||||||||||
Site consolidation costs, impairments and other items | — |
|
238 |
|
|
257 |
|
|
822 |
|
||||||
Total non-GAAP adjustments to operating income |
$ |
722 |
|
$ |
688 |
|
$ |
4,606 |
|
$ |
2,832 |
|
||||
Operating income, excluding non-GAAP adjustments |
$ |
35,107 |
|
$ |
32,809 |
|
$ |
108,335 |
|
$ |
107,725 |
|
||||
Non-GAAP operating income as a % of revenue |
|
26.5 |
% |
|
25.9 |
% |
|
26.7 |
% |
|
27.5 |
% |
||||
Depreciation and amortization |
$ |
4,895 |
|
$ |
4,811 |
|
$ |
14,198 |
|
$ |
14,565 |
|
||||
Capital expenditures |
$ |
5,818 |
|
$ |
8,166 |
|
$ |
14,979 |
|
$ |
18,105 |
|
||||
Discovery and Safety Assessment | ||||||||||||||||
Revenue |
$ |
420,079 |
|
$ |
352,257 |
|
$ |
1,179,793 |
|
$ |
958,665 |
|
||||
Operating income |
|
64,995 |
|
|
62,909 |
|
|
175,214 |
|
|
160,391 |
|
||||
Operating income as a % of revenue |
|
15.5 |
% |
|
17.9 |
% |
|
14.9 |
% |
|
16.7 |
% |
||||
Add back: | ||||||||||||||||
Amortization related to acquisitions |
|
21,560 |
|
|
16,204 |
|
|
58,067 |
|
|
39,796 |
|
||||
Severance |
|
1,848 |
|
|
30 |
|
|
2,533 |
|
|
973 |
|
||||
Acquisition related adjustments (3) |
|
4,524 |
|
|
269 |
|
|
8,516 |
|
|
1,466 |
|
||||
Site consolidation costs, impairments and other items |
|
(207 |
) |
|
26 |
|
|
(207 |
) |
|
(117 |
) |
||||
Total non-GAAP adjustments to operating income |
$ |
27,725 |
|
$ |
16,529 |
|
$ |
68,909 |
|
$ |
42,118 |
|
||||
Operating income, excluding non-GAAP adjustments |
$ |
92,720 |
|
$ |
79,438 |
|
$ |
244,123 |
|
$ |
202,509 |
|
||||
Non-GAAP operating income as a % of revenue |
|
22.1 |
% |
|
22.6 |
% |
|
20.7 |
% |
|
21.1 |
% |
||||
Depreciation and amortization |
$ |
39,898 |
|
$ |
31,433 |
|
$ |
111,231 |
|
$ |
83,262 |
|
||||
Capital expenditures |
$ |
21,141 |
|
$ |
10,800 |
|
$ |
45,130 |
|
$ |
34,496 |
|
||||
Manufacturing Support | ||||||||||||||||
Revenue |
$ |
115,326 |
|
$ |
106,227 |
|
$ |
344,523 |
|
$ |
314,706 |
|
||||
Operating income |
|
39,253 |
|
|
33,266 |
|
|
103,893 |
|
|
95,904 |
|
||||
Operating income as a % of revenue |
|
34.0 |
% |
|
31.3 |
% |
|
30.2 |
% |
|
30.5 |
% |
||||
Add back: | ||||||||||||||||
Amortization related to acquisitions |
|
2,204 |
|
|
2,217 |
|
|
6,802 |
|
|
6,816 |
|
||||
Severance |
|
248 |
|
— |
|
549 |
|
|
870 |
|
||||||
Acquisition related adjustments (3) |
|
62 |
|
|
(15 |
) |
|
218 |
|
— | ||||||
Site consolidation costs, impairments and other items |
|
180 |
|
— |
|
1,485 |
|
|
159 |
|
||||||
Total non-GAAP adjustments to operating income |
$ |
2,694 |
|
$ |
2,202 |
|
$ |
9,054 |
|
$ |
7,845 |
|
||||
Operating income, excluding non-GAAP adjustments |
$ |
41,947 |
|
$ |
35,468 |
|
$ |
112,947 |
|
$ |
103,749 |
|
||||
Non-GAAP operating income as a % of revenue |
|
36.4 |
% |
|
33.4 |
% |
|
32.8 |
% |
|
33.0 |
% |
||||
Depreciation and amortization |
$ |
5,990 |
|
$ |
5,709 |
|
$ |
17,577 |
|
$ |
17,313 |
|
||||
Capital expenditures |
$ |
6,421 |
|
$ |
2,709 |
|
$ |
14,299 |
|
$ |
12,731 |
|
||||
Unallocated Corporate Overhead |
$ |
(45,831 |
) |
$ |
(43,934 |
) |
$ |
(140,474 |
) |
$ |
(132,287 |
) |
||||
Add back: | ||||||||||||||||
Severance | — |
|
4,619 |
|
— |
|
5,278 |
|
||||||||
Acquisition related adjustments (3) |
|
5,296 |
|
|
1,801 |
|
|
23,188 |
|
|
15,698 |
|
||||
Other items (4) |
$ |
379 |
|
$ |
— |
$ |
1,408 |
|
$ |
— |
||||||
Total non-GAAP adjustments to operating expense |
$ |
5,675 |
|
$ |
6,420 |
|
$ |
24,596 |
|
$ |
20,976 |
|
||||
Unallocated corporate overhead, excluding non-GAAP adjustments |
$ |
(40,156 |
) |
$ |
(37,514 |
) |
$ |
(115,878 |
) |
$ |
(111,311 |
) |
||||
Total | ||||||||||||||||
Revenue |
$ |
667,951 |
|
$ |
585,295 |
|
$ |
1,930,088 |
|
$ |
1,664,566 |
|
||||
Operating income |
$ |
92,802 |
|
$ |
84,362 |
|
$ |
242,362 |
|
$ |
228,901 |
|
||||
Operating income as a % of revenue |
|
13.9 |
% |
|
14.4 |
% |
|
12.6 |
% |
|
13.8 |
% |
||||
Add back: | ||||||||||||||||
Amortization related to acquisitions |
|
24,105 |
|
|
18,806 |
|
|
65,911 |
|
|
47,814 |
|
||||
Severance and executive transition costs |
|
2,477 |
|
|
4,714 |
|
|
4,188 |
|
|
7,929 |
|
||||
Acquisition related adjustments (2)(3) |
|
9,882 |
|
|
2,055 |
|
|
34,123 |
|
|
17,164 |
|
||||
Site consolidation costs, impairments and other items (4) |
|
352 |
|
|
264 |
|
|
2,943 |
|
|
864 |
|
||||
Total non-GAAP adjustments to operating income |
$ |
36,816 |
|
$ |
25,839 |
|
$ |
107,165 |
|
$ |
73,771 |
|
||||
Operating income, excluding non-GAAP adjustments |
$ |
129,618 |
|
$ |
110,201 |
|
$ |
349,527 |
|
$ |
302,672 |
|
||||
Non-GAAP operating income as a % of revenue |
|
19.4 |
% |
|
18.8 |
% |
|
18.1 |
% |
|
18.2 |
% |
||||
Depreciation and amortization |
$ |
51,758 |
|
$ |
43,592 |
|
$ |
146,262 |
|
$ |
120,198 |
|
||||
Capital expenditures |
$ |
35,163 |
|
$ |
22,439 |
|
$ |
76,675 |
|
$ |
71,378 |
|
(1) Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.
(2) This amount represents a
(3) These adjustments are related to the evaluation and integration of acquisitions, which primarily include transaction, third-party integration, and certain compensation costs, and fair value adjustments associated with contingent consideration.
(4) This amount relates to third-party costs, net of insurance reimbursements, associated with the remediation of the unauthorized access into the Company's information systems which was detected in
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ||||||||||||||||
SCHEDULE 5 RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)(1) (in thousands, except per share data) |
||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 28, 2019 | September 29, 2018 | September 28, 2019 | September 29, 2018 | |||||||||||||
Net income attributable to common shareholders |
$ |
72,810 |
|
$ |
60,368 |
|
$ |
171,671 |
|
$ |
166,708 |
|
||||
Less: Income from discontinued operations, net of income taxes | — | — | — |
|
1,506 |
|
||||||||||
Net income from continuing operations attributable to common shareholders |
|
72,810 |
|
|
60,368 |
|
|
171,671 |
|
|
165,202 |
|
||||
Add back: | ||||||||||||||||
Non-GAAP adjustments to operating income (Refer to Schedule 4) |
|
36,816 |
|
|
25,839 |
|
|
107,165 |
|
|
73,771 |
|
||||
Write-off of deferred financing costs and fees related to debt refinancing | — | — | — |
|
5,060 |
|
||||||||||
Venture capital (gains) losses |
|
598 |
|
|
(5,376 |
) |
|
(5,724 |
) |
|
(22,760 |
) |
||||
Tax effect of non-GAAP adjustments: | ||||||||||||||||
Tax effect from U.S. Tax Reform (2) | — |
|
(2,800 |
) |
— |
|
(2,800 |
) |
||||||||
Tax effect from divestiture of CDMO business | — |
|
(1,000 |
) |
— |
|
(1,000 |
) |
||||||||
Non-cash tax benefit related to international financing structure (3) |
|
(20,368 |
) |
— |
|
(20,368 |
) |
— | ||||||||
Tax effect of the remaining non-GAAP adjustments |
|
(6,073 |
) |
|
(5,476 |
) |
|
(18,443 |
) |
|
(11,822 |
) |
||||
Net income from continuing operations attributable to common shareholders, excluding non-GAAP adjustments |
$ |
83,783 |
|
$ |
71,555 |
|
$ |
234,301 |
|
$ |
205,651 |
|
||||
Weighted average shares outstanding - Basic |
|
48,818 |
|
|
48,310 |
|
|
48,682 |
|
|
48,098 |
|
||||
Effect of dilutive securities: | ||||||||||||||||
Stock options, restricted stock units, performance share units and restricted stock |
|
897 |
|
|
1,016 |
|
|
945 |
|
|
1,020 |
|
||||
Weighted average shares outstanding - Diluted |
|
49,715 |
|
|
49,326 |
|
|
49,627 |
|
|
49,118 |
|
||||
Earnings per share from continuing operations attributable to common shareholders | ||||||||||||||||
Basic |
$ |
1.49 |
|
$ |
1.25 |
|
$ |
3.53 |
|
$ |
3.43 |
|
||||
Diluted |
$ |
1.46 |
|
$ |
1.22 |
|
$ |
3.46 |
|
$ |
3.36 |
|
||||
Basic, excluding non-GAAP adjustments |
$ |
1.72 |
|
$ |
1.48 |
|
$ |
4.81 |
|
$ |
4.28 |
|
||||
Diluted, excluding non-GAAP adjustments |
$ |
1.69 |
|
$ |
1.45 |
|
$ |
4.72 |
|
$ |
4.19 |
|
(1)Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.
(2)This adjustment is related to the refinement of one-time charges associated with the enactment of U.S. Tax Reform related to the transition tax on unrepatriated earnings (also known as the toll tax), and the revaluation of U.S. federal net deferred tax liabilities.
(3)This adjustment relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ||||||||||||
SCHEDULE 6 RECONCILIATION OF GAAP REVENUE GROWTH TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) (1) |
||||||||||||
Three Months Ended September 28, 2019 | Total CRL | RMS Segment | DSA Segment | MS Segment | ||||||||
Revenue growth, reported |
14.1 |
% |
4.5 |
% |
19.3 |
% |
8.6 |
% |
||||
Decrease (increase) due to foreign exchange |
1.3 |
% |
1.3 |
% |
1.1 |
% |
2.2 |
% |
||||
Contribution from acquisitions (2) |
(7.5 |
)% |
— |
% |
(12.5 |
)% |
(0.2 |
)% |
||||
Non-GAAP revenue growth, organic (3) |
7.9 |
% |
5.8 |
% |
7.9 |
% |
10.6 |
% |
||||
Nine Months Ended September 28, 2019 | Total CRL | RMS Segment | DSA Segment | MS Segment | ||||||||
Revenue growth, reported |
16.0 |
% |
3.7 |
% |
23.1 |
% |
9.5 |
% |
||||
Decrease (increase) due to foreign exchange |
1.9 |
% |
2.3 |
% |
1.4 |
% |
3.1 |
% |
||||
Contribution from acquisitions (2) |
(8.9 |
)% |
— |
% |
(15.4 |
)% |
(0.2 |
)% |
||||
Non-GAAP revenue growth, organic (3) |
9.0 |
% |
6.0 |
% |
9.1 |
% |
12.4 |
% |
(1)Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.
(2)The contribution from acquisitions reflects only completed acquisitions. Manufacturing Support includes an immaterial acquisition of an Australian Microbial Solutions business.
(3)Organic revenue growth is defined as reported revenue growth adjusted for acquisitions and foreign exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005189/en/
Source:
Investor Contacts:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com
Media Contact:
Amy Cianciaruso
Corporate Vice President,
Public Relations
781.222.6168
amy.cianciaruso@crl.com